OneMedNet reported total revenue of $177 000 for the third quarter of 2025, up from $142 000 in the same period last year, while the net loss narrowed to $741 000 from $2.06 million in Q3 2024. The earnings per share fell to a loss of $0.01, an improvement over the $0.07 loss reported a year earlier, reflecting tighter cost control and a higher mix of higher‑margin contracts.
Bookings for the quarter reached $1.1 million, an 815% increase year‑over‑year, and inbound demand grew 4.5‑fold. The surge is driven by the company’s AI‑powered iRWD platform and its partnership with Palantir, which has accelerated the rollout of a subscription‑based SaaS model that is expected to generate recurring revenue. The expanded network now includes more than 1,750 healthcare sites, providing a broader data footprint for the platform.
OneMedNet also highlighted a significant balance‑sheet improvement, reporting a $1.9 million reduction in total liabilities during the quarter, part of a $14.3 million year‑to‑date decline. The company completed a $0.5 million private placement from an insider, further strengthening its capital position and supporting ongoing investment in AI capabilities.
CEO Aaron Green emphasized that the company’s focus on cost discipline and strategic capital infusions has enabled a more resilient sales pipeline and larger deal sizes. “The combination of reduced debt and strategic capital infusions allows us to focus on opportunities that deliver long‑term value,” he said, noting that the partnership with Palantir is accelerating the delivery of subscription models and improving access to high‑quality real‑world data.
The announcement also confirmed OneMedNet’s pivot away from its legacy BEAM platform toward the iRWD solution, a move that aligns with the company’s broader strategy to capture higher‑value markets and build recurring revenue streams. The shift is expected to enhance the company’s competitive positioning in the AI‑driven medical imaging data space.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.